Lentiviral Vector Transduced CD34 Plus Cells(NIAID)

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameLentiviral Vector Transduced CD34 Plus Cells(NIAID)

Drug Alias NameCryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47(NIAID)pCCLCHIM-p47

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionGene transference

TargetsNot applicable

Therapy Area/IndicationsGenetic Diseases, InbornGranulomatous Disease, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

Inactive CompaniesN/A

Active IndicationsGenetic Diseases, InbornGranulomatous Disease, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A